hotspot -WSS

hotspot

author：fashion 2025-09-29 23:04:13 - browse：987

Bill Cassidy speaks with his palm facing upward during a hearing on prescription drug costs — politics coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — Republicans in Congress might try to use a technical maneuver to block the Biden administration from using so-called march-in rights to seize pharmaceutical patents and lower drug prices.

The Biden White House wants to ignore certain patents for inventions that were developed with government funding, at least in extenuating circumstances. Taxpayers have helped fund the research of a substantial number of drugs sold in the United States though the National Institutes of Health, so the proposal would let the government bring in generic drugmakers to make medicines even before their patents expire.

Until the Biden administration, the government refused to consider that an invention’s price could justify the “march in” maneuver. But the White House in December issued a draft framework for the NIH to more broadly use the power, including in cases where price is a concern.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

WSS

Even great ERs can’t make up for American health disparities

Do digital therapeutics have a future in medicine?

What we need to know about Arena Bioworks

United colonoscopy coverage change 'may cost lives,' doctors say

Time to name cancers by genetics, not organ of origin, expert says

FDA drug safety: Singulair case shows systemic surveillance flaws

leisure time

hotspot

entertainment

Drug repurposing or repositioning? The language matters

The real point of Kenneth Smith’s execution by nitrogen gas

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ARCH Venture Partners is raising $3 billion for a life sciences fund

Drug repurposing or repositioning? The language matters

In Memoriam: Notable people who died in 2023

Medicare proposal to cover medical devices draws a mixed reaction

ARCH Venture Partners is raising $3 billion for a life sciences fund

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Anesthesiologist group: stop taking Ozempic before surgery

In age of alternative facts, a scholarly course on calling out crap

Peter Hotez and the public health issue of online harassment

A $475,000 price tag for a new cancer drug: crazy or meh?

Wikipedia

explore

hotspot

hotspot